Magnus Pharma launches the novel oral anticoagulant Rivaroxaban in the Nepalese market. Magnus has launched the molecule with the brand name COAGRIV.
What is Rivaroxaban ?
Rivaroxaban is the medicine used as blood thinner and falls in the class of novel oral anticoagulant (NOAC). It is the medication used to treat and prevent blood clots. Specifically it is used to prevent the risk of stroke in people with atrial fibrillation , as well as , treat deep vein thrombosis and pulmonary emboli and prevent blood clots formation following hip or knee surgery . Rivaroxaban was approved by FDA in the year 2011. It is a highly selective direct factor Xa inhibitor with a rapid onset of action. Inhibition of Factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi.
Why is Rivaroxaban a better choice of anticoagulant ?
For around more than 70 years, warfarin has been the mainstay oral anticoagulant drug. But there have always been a major limitations while using warfarin , the most profounding being the dose variability problem. Due to this , patient on warfarin have to do the regular monitoring of blood termed as International Normalized Ratio (INR) monitoring , which can be quit tedious . Also , there are several food and drug interations with warfarin. The novel oral anticoagulant Rivaroxaban eliminates all these sorts of limitation seen in warfarin, thus increasing the patient compliance. In those with non-valvular atrial fibrillation, it appears to be as effective as warfarin in preventing ischemic stroke and embolic events. Rivaroxaban is associated with lower rates of serious and fatal bleeding events than warfarin.